CFI-402257 + Paclitaxel for Breast Cancer

This trial tests a new drug, CFI-402257, combined with the standard chemotherapy drug paclitaxel, to determine if it slows breast cancer growth more effectively than paclitaxel alone. The trial targets women with advanced or recurring breast cancer that cannot be surgically removed and for whom no cure exists. Ideal candidates have previously received treatment for breast cancer, require further systemic therapy, and can take oral medications. Participants should not have HER2-positive breast cancer or active infections. As a Phase 1/Phase 2 trial, this research aims to understand how the treatment works in people and measure its effectiveness in an initial, smaller group, offering participants the chance to contribute to early-stage cancer treatment advancements.

The trial protocol does not specify if you need to stop taking your current medications, but there is a requirement for a 'washout period' (time without taking certain medications) for some treatments. It's best to discuss your specific medications with the trial team to see if they are allowed.

Previous studies have shown that the combination of CFI-402257 and paclitaxel is generally safe for patients with HER2-negative breast cancer. Research indicates that most people tolerate this treatment well, with usually manageable side effects. Although some side effects were reported, they were not severe for most participants. This suggests that the treatment is relatively safe, though some risks remain. As with any new treatment, weighing both the potential benefits and side effects is important.¹²³⁴⁵

Researchers are excited about CFI-402257 combined with Paclitaxel for breast cancer because it introduces a novel approach by using an oral drug, CFI-402257, which targets specific cancer cell mechanisms. Unlike traditional treatments that mainly rely on chemotherapy, this combination promises a more targeted attack on cancer cells, potentially reducing side effects and improving effectiveness. Additionally, the intermittent dosing schedule of CFI-402257 might offer patients a more manageable treatment experience compared to continuous regimens.

Research shows that CFI-402257, a new drug for breast cancer, can slow tumor growth in lab tests. In this trial, participants will receive a combination of CFI-402257 and the common chemotherapy drug paclitaxel. Early studies indicate that 11-14% of patients with advanced HER2-negative breast cancer responded to this combination treatment, suggesting it might work for some individuals. The combination is also considered safe for most patients, as it doesn't cause severe side effects. Overall, while early data remains limited, there is hope that this treatment could offer more benefits than using paclitaxel alone.¹²⁴⁵⁶